Entry Point Capital, LLC Cytokinetics Inc Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 8,825 shares of CYTK stock, worth $417,952. This represents 0.27% of its overall portfolio holdings.
Number of Shares
8,825Holding current value
$417,952% of portfolio
0.27%Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
409Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$695 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$557 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$459 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$368 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$306 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.46B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...